Skip to main content

Advertisement

Table 3 Tumor growth inhibition and tumor growth delay of evofosfamide in NPC xenograft models

From: Efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in nasopharyngeal carcinoma in vitro and in vivo

Group TGI (%) TGD500 (day) TGD1000 (day)
Control 0 10.4 13.2
DDP 42 11.4 18.3
Evofosfamide 50 μmol/L 43 11.2 15.4
Evofosfamide 50 μmol/L + DDP 49 11.3 18.9
Evofosfamide 75 μmol/L 55 11.4 21.2
Evofosfamide 75 μmol/L + DDP 71 11.2 N/A
  1. TGD500 and TGD1000 were determined as the average increase in time for the treated tumor to reach a size of 500 or 1000 mm3 compared with the control group
  2. TGI tumor growth inhibition, TGD tumor growth delay